StageZero Life Sciences (SZLS) Q2 2024 earnings summary

Executive summary

• Focused on operational and strategic changes in H1 2024 to improve efficiency and competitiveness, including laboratory relocation and new partnerships for Aristotle test.

• CareOncology expanded operations in US/Canada and UK, introducing new programs and outreach to meet patient demand.

Financial highlights

• Generated $0.912M in revenue for H1 2024, down from $1.555M in H1 2023; Q2 2024 revenue was $0.390M, down from $0.693M in Q2 2023.

• Net loss for H1 2024 was $1.036M ($0.01/share), improved from $2.214M loss in H1 2023 ($0.02/share).

• Q2 2024 net loss was $0.650M ($0.00/share), compared to $0.401M loss in Q2 2023 ($0.00/share).

• Q3 revenues are showing an increase over Q1 and Q2, with expectations for further ramp-up in Q4.

Outlook and guidance

• Strategic partnerships for Aristotle test expected to drive revenue growth in H2 2024.

• AVRT program to be introduced to key lab partnerships by end of 2024.

• UK and European operations being repositioned for expansion, with new programs and outreach initiatives.

• Anticipates filing Q3 financials on time by November 14, 2024.